Publicaciones en colaboración con investigadores/as de Hospital Ramón y Cajal (26)

2024

  1. Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry

    Therapeutic Advances in Gastroenterology, Vol. 17

  2. Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn's Disease (Versus-CD): Data from the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 18, Núm. 1, pp. 65-74

  3. Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)

    Alimentary Pharmacology and Therapeutics

2023

  1. Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91

  2. Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety

    American Journal of Gastroenterology, Vol. 118, Núm. 7, pp. 1237-1247

  3. Splanchnic Vein Thrombosis in Inflammatory Bowel Disease: An Observational Study from the ENEIDA Registry and Systematic Review

    Journal of Clinical Medicine, Vol. 12, Núm. 23

2022

  1. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study

    Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736

  2. Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry

    Digestive and Liver Disease, Vol. 54, Núm. 5, pp. 635-641

  3. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

    Journal of Clinical Medicine, Vol. 11, Núm. 15

2021

  1. Impact of biological agents on postsurgical complications in inflammatory bowel disease: A multicentre study of geteccu

    Journal of Clinical Medicine, Vol. 10, Núm. 19

  2. Tofacitinib in ulcerative colitis: Real-world evidence from the ENEIDA registry

    Journal of Crohn's and Colitis, Vol. 15, Núm. 1, pp. 35-42

2020

  1. Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn’s disease

    United European Gastroenterology Journal, Vol. 8, Núm. 9, pp. 1056-1066

2019

  1. Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study

    Journal of Crohn's & colitis, Vol. 13, Núm. 12, pp. 1492-1500

2017

  1. P567Early diagnosis of anthracycline induced cardiotoxicity in a swine model by serial multiparametric cardiac magnetic resonance

    European Heart Journal, Vol. 38, Núm. suppl_1

2015

  1. Susceptibility and tolerance of human gut culturable aerobic microbiota to wine polyphenols

    Microbial Drug Resistance, Vol. 21, Núm. 1, pp. 17-24

2013

  1. Análisis de la implantación de prácticas seguras en los sistemas automatizados de dispensación de medicamentos

    Farmacia Hospitalaria, Vol. 37, Núm. 6, pp. 469-481

2011

  1. Elaboración de una relación de nombres de medicamentos similares en los que se recomienda utilizar letras mayúsculas resaltadas

    Farmacia Hospitalaria, Vol. 35, Núm. 5, pp. 225-235

2010

  1. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer

    Breast Cancer Research and Treatment, Vol. 123, Núm. 1, pp. 149-157

2008

  1. Methylmalonic acidaemia: Examination of genotype and biochemical data in 32 patients belonging to mut, cblA or cblB complementation group

    Journal of Inherited Metabolic Disease, Vol. 31, Núm. 1, pp. 55-66

2003

  1. Population pharmacokinetics of high dose ibuprofen in cystic fibrosis

    Archives of Disease in Childhood, Vol. 88, Núm. 12, pp. 1128-1130